End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18
End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18
复制标题
DOI：
10.2807/1560-7917.es.2019.24.31.1800488
复制
发表时间：
2019-08-01
期刊：
影响因子：
19
通讯作者：
Zambon, Maria
中科院分区：
文献类型：
--
作者：
Pebody, Richard;Djennad, Abdelmajid;Zambon, Maria
背景资料：在英国（UK），在最近的流感季节，为儿童提供四价减毒活流感疫苗（LAIV 4），而符合条件的成年人主要是三价灭活疫苗（TIV）。目的：估计英国2017/18季末调整后的疫苗有效性（aVE）和英格兰鸡蛋或组织中培养的流感病毒抗体的血清阳性率。方法：本观察性研究采用测试阴性病例对照方法来估计初级保健中的aVE。以人群为基础的血清阳性率调查使用剩余年龄分层样本。结果：流感病毒A（H3 N2）（特别是3C亚群）。2a 2）和B（主要是B/Yamagata/16/88-谱系，与四价疫苗B病毒组分相似，但与TIV错配）占优势。针对所有流感的所有年龄段aVE为15%（95%置信区间（CI）：-6.3至32）;针对甲型（H3 N2）的aVE为-16.4%（95% CI：-59.3至14.9）;针对B的aVE为24.7%（95% CI：1.1至42.7）;针对甲型（H1N1）pdm 09的aVE为66.3%（95% CI：33.4至82.9）。2-17奥尔兹儿童LAIV 4 aVE为26.9%，（95% CI：-32.6至59.7）针对所有流感; -75.5%（95% CI：-289.6至21）;对B为60.8%（95% CI：8.2至83.3）;对A（H1N1）pdm 09为90.3%（95% CI：16.4至98.9）。对于≥ 18奥尔兹，抗流感B的TIV aVE为1.9%（95% CI：-63.6至41.2）。2017年，除15-24奥尔兹外，所有人群中识别组织生长A（H3 N2）病毒的抗体血清阳性率均显著低于识别鸡蛋生长病毒的抗体。结论：总体aVE较低，原因是对A（H3 N2）无有效性，可能与疫苗病毒卵适应和新的A（H3 N2）亚群出现有关。TIV对B型流感病毒无效。LAIV 4对流感病毒B和A（H1N1）pdm 09有效。
Background: In the United Kingdom (UK), in recent influenza seasons, children are offered a quadrivalent live attenuated influenza vaccine (LAIV4), and eligible adults mainly trivalent inactivated vaccine (TIV). Aim: To estimate the UK end-of-season 2017/18 adjusted vaccine effectiveness (aVE) and the seroprevalence in England of antibodies against influenza viruses cultured in eggs or tissue. Methods: This observational study employed the test-negative case-control approach to estimate aVE in primary care. The population-based seroprevalence survey used residual age-stratified samples. Results: Influenza viruses A(H3N2) (particularly subgroup 3C. 2a2) and B (mainly B/Yamagata/16/88-lineage, similar to the quadrivalent vaccine B-virus component but mismatched to TIV) dominated. All-age aVE was 15% (95% confidence interval (CI): -6.3 to 32) against all influenza; -16.4% (95% CI: -59.3 to 14.9) against A(H3N2); 24.7% (95% CI: 1.1 to 42.7) against B and 66.3% (95% CI: 33.4 to 82.9) against A(H1N1) pdm09. For 2-17 year olds, LAIV4 aVE was 26.9% (95% CI: -32.6 to 59.7) against all influenza; -75.5% (95% CI: -289.6 to 21) against A(H3N2); 60.8% (95% CI: 8.2 to 83.3) against B and 90.3% (95% CI: 16.4 to 98.9) against A(H1N1) pdm09. For >= 18 year olds, TIV aVE against influenza B was 1.9% (95% CI: -63.6 to 41.2). The 2017 seroprevalence of antibody recognising tissue-grown A(H3N2) virus was significantly lower than that recognising egg-grown virus in all groups except 15-24 year olds. Conclusions: Overall aVE was low driven by no effectiveness against A(H3N2) possibly related to vaccine virus egg-adaption and a new A(H3N2) subgroup emergence. The TIV was not effective against influenza B. LAIV4 against influenza B and A(H1N1) pdm09 was effective.